Professor Wai-Keung LEUNG
Clinical Trials Centre, The University of Hong Kong
Professor Richard WONG
Acting President & Vice-Chancellor
The University of Hong Kong
Dr Stephen WONG
Chief Executive’s Policy Unit, HKSAR Government
Mr Henry FAN
Acknowledgement of Sponsors
Live Music Performance
HKU Clinical Trials Centre Long Service Award Ceremony &
Clinical Research Trainee Programme 2022/23 Graduation Ceremony
Live Music Performance
Holiday Inn Golden Mile Hong Kong,
50 Nathan Road, Tsim Sha Tsui, Hong Kong
.(in alphabetical order)
Located in Hong Kong Island South, Gleneagles Hospital Hong Kong (Gleneagles) is a multi-specialty private hospital with cutting-edge medical equipment and a comprehensive range of clinical services spanning more than 35 specialties and subspecialties. As Hong Kong’s top-notch private teaching hospital, Gleneagles also contributes to the training and development of healthcare professionals and advancement of clinical research. Gleneagles is jointly developed by IHH Healthcare and NWS Holdings Limited, with The University of Hong Kong as its exclusive clinical partner.
Gleneagles Hospital Hong Kong is part of IHH Healthcare, one of the world’s largest healthcare providers. With its full spectrum of integrated services, dedicated people, reach and scale, and commitment to quality and safety, IHH aspires to be the world’s most trusted healthcare services network, united by a single purpose: to touch lives and transform care.
More information on Gleneagles Hospital Hong Kong can be found at https://gleneagles.hk.
GSK is a global biopharma company with the ambition and purpose to unite science, technology and talent to get ahead of disease together.
GSK prioritises innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is GSK R&D focus on the science of the immune system, human genetics and advanced technologies, and world-leading capabilities in vaccines and medicines development. GSK will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit: www.roche.com
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services.
Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.
Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and Twitter @Fortrea.
At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 35 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases.
Through bold and transformative science, we’re driving innovation that has the potential to become the next generation of life-changing medicines. Our ambition is evident in our mission. Because the impossible is not impossible. It’s what’s next.
Novotech is internationally recognized as the leading Asia Pacific centred Biotech Contract Research Organization (CRO) with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services and FDA regulatory expertise and has experience in over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 3000 staff globally and 34 office locations.
For more information, please visit: https://novotech-cro.com
Nuance Pharma is an innovation focused biopharma company, with late-stage clinical pipeline and commercial stage asset portfolio across respiratory, emergency care, iron deficiency anemia and pain management.
With the mission to address critical unmet needs in Asia Pacific, Nuance deploys the Dual Wheel model that develops a leading innovative pipeline, while maintaining a self-sustainable commercial operation in China and Asia.
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are committed to moving our customers through their development journey efficiently and cost-effectively.
Since our inception in 2004, we have a proven track record of project delivery with 3,300+ drug clinical studies and 780+ medical device clinical studies around the world, and supported the clinical studies of 73 approved innovative drugs in China. According to Frost & Sullivan report, Tigermed is the only Chinese company that was ranked as top 10 clinical CROs globally in 2022 by revenue.
Tigermed currently represents a worldwide network of more than 100 subsidiaries and 180 service locations, with over 10,000 employees across Asia Pacific, Europe, North & South America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients’ needs, and ultimately saving lives.
For more information: www.tigermedgrp.com
© 2023 Clinical Trials Centre, The University of Hong Kong.
All Rights Reserved.